TCRR — TCR2 Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $58.11m
- -$52.20m
- 35
- 47
- 64
- 47
Annual income statement for TCR2 Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 26.5 | 51.4 | 68.7 | 99.7 | 153 |
| Operating Profit | -26.5 | -51.4 | -68.7 | -99.7 | -153 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -24.3 | -47.5 | -67 | -99.5 | -152 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -24.3 | -47.6 | -67.1 | -99.8 | -152 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -24.3 | -47.6 | -67.1 | -99.8 | -152 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -61.5 | -97.5 | -67.1 | -99.8 | -152 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.57 | -4.62 | -2.4 | -2.57 | -3.41 |